Smith & Nephew (LON:SN) Price Target Lowered to GBX 1,250 at Royal Bank Of Canada

Smith & Nephew (LON:SN) had its target price cut by stock analysts at Royal Bank Of Canada from GBX 1,350 to GBX 1,250 in a research report issued to clients and investors on Thursday,London Stock Exchange reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 11.41% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,400 price objective on shares of Smith & Nephew in a report on Thursday, July 30th. Citigroup cut Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 target price on shares of Smith & Nephew in a research note on Tuesday, July 21st. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,500 price target on shares of Smith & Nephew in a research report on Wednesday. Finally, Berenberg Bank restated a “hold” rating and set a GBX 13 price objective on shares of Smith & Nephew in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Smith & Nephew currently has a consensus rating of “Hold” and an average target price of GBX 1,172.56.

Smith & Nephew Stock Down 6.3%

SN stock opened at GBX 1,122 on Thursday. The business has a fifty day moving average of GBX 1,135.98 and a 200-day moving average of GBX 1,194.09. The firm has a market capitalization of £12.30 billion, a P/E ratio of 40.40, a P/E/G ratio of 0.46 and a beta of 0.69. The company has a quick ratio of 0.84, a current ratio of 2.14 and a debt-to-equity ratio of 73.07.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.